赫赛汀联合紫杉醇新辅助化疗对HER-2阳性乳腺癌细胞增殖活力的影响  

Effect of Herceptin combined with paclitaxel neoadjuvant chemotherapy on proliferation viability of HER-2 positive breast cancer cell

作　　者：何敏 邓丽聪 HE Min;DENG Li-cong(Department of Pharmacy,the First People＇s Hospital of Ziyang,Ziyang 641300,China)

机构地区：[1]资阳市第一人民医院药剂科,四川资阳641300

出　　处：《海南医学院学报》2018年第17期1603-1606,共4页Journal of Hainan Medical University

基　　金：四川省卫生厅科研课题(重恶性疾病攻关专项)(130609)~~

摘　　要：目的:研究赫赛汀联合紫杉醇新辅助化疗对HER-2阳性乳腺癌细胞增殖活力的影响。方法:选择2015年2月～2017年10月期间在资阳市第一人民医院诊断为乳腺癌并接受新辅助化疗的患者作为研究对象,随机分为接受赫赛汀联合多西紫杉醇化疗的实验组、接受表柔比星联合多西紫杉醇化疗的对照组。化疗结束后,测定血清中肿瘤标志物的含量;手术切除后,取乳腺癌病灶并测定增殖基因及抑癌基因的mRNA表达量。结果:两组间肿瘤标志物含量以及增殖基因、抑癌基因表达量的比较差异有统计学意义(P<0.05);实验组患者血清中CA15-3、IGF-1、TSGF、TPS的含量以及乳腺癌病灶内CyclinD1、PCNA、Bcl-2、Survivin、VEGF的mRNA表达量均低于对照组,乳腺癌病灶内PTEN、Bax、ARID1A、FasL、Caspase-3的mRNA表达量均高于对照组。结论:赫赛汀联合紫杉醇新辅助化疗能够较表柔比星联合紫杉醇化疗更为有效的抑制HER-2阳性乳腺癌细胞的增殖活力。Objective：To study the effect of Herceptin combined with paclitaxel neoadjuvant chemotherapy on the proliferation viability of HER-2 positive breast cancer cell.Methods：Patients diagnosed as breast cancer and treated by neoadjuvant chemotherapy in the First People’s Hospital of Ziyang from February 2015 to October 2017 were selected and randomly divided into experimental group and control group.The experimental group received Herceptin and docetaxel chemotherapy,while control group received epirubicin combined with docetaxel chemotherapy.After chemotherapy,content of tumor markers in serum were measured and after the operation,the expression of the proliferation and tumor suppressor genes in breast cancer were measured.Results：Tumor markers content,proliferation gene and tumor suppressor gene expression of two groups had statistical significance（P〈0.05）;CA15-3,IGF-1,TSGF,TPS contents in serum and mRNA expression of CyclinD1,PCNA,Bcl-2,Survivin,VEGF in breast cancer were lower than the control group,mRNA expression of PTEN,Bax,ARID1 A,FasL and Caspase-3 in breast cancer were higher than the control group（P〈0.05）.Conclusion：Herceptin combined with paclitaxel neoadjuvant chemotherapy can more effectively inhibit proliferation activity of HER-2 positive breast cancer cell than epirubicin combined paclitaxel chemotherapy.

关 键 词：乳腺癌 人表皮生长因子受体-2 新辅助化疗 赫赛汀 增殖 

分 类 号：R737.9[医药卫生—肿瘤]